One arm of the bispecific antibody AFM13 binds to CD30 surface antigens on cHL HRS cells, and the other arm binds to CD16A surface antigens on NK cells, leading to NK cell–mediated destruction of the HRS cells. This therapeutic attack is dramatically enhanced by adding pembrolizumab, which blocks the protection from immune attack that HRS cells employ by elaborating PD-L1.